a favorable trendP = 0.045
A multicenter randomized study in Hong Kong (NPC 0501 Trial) [ 31 ] regarding various chemotherapy schemes recently reported its preliminary results that induction cisplatin and capecitabine (PX) presented a favorable trend in progression-free survival compared to adjuvant cisplatin and fluorouracil (PF) ( P = 0.045).